National trial shows carotid artery surgery and stenting equally effective in preventing stroke

May 26, 2010, Mayo Clinic

Physicians now have two safe and effective options to treat their patients at risk for stroke, says a researcher at Mayo Clinic who led a large, NIH-funded, national clinical trial testing surgery or use of a stent to open a blocked carotid artery.

The results, published in the May 26 online issue of the New England Journal of Medicine, also show "excellent safety and long term results for patients with warning signs for as well as for patients without such warning signs," says the national principal investigator, Thomas G. Brott, M.D., professor of neurology and director for research at the Mayo Clinic campus in Florida.

Compared to other large international stroke prevention trials, Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) is unique in that approximately half of enrolled patients did not have symptoms of carotid disease, while the other half had experienced recent symptoms such as a minor non-disabling stroke or (TIA).

The CREST results can inform treatment decisions for both groups of patients, in contrast to results from recent trials completed in Europe. This is important because more than half of the approximately 140,000 carotid surgeries and stent procedures performed in the U.S. each year are performed for patients without symptoms.

Researchers say that while the findings show surgery and stenting had very good long-term outcomes, they differed in the weeks following the procedure — patients who received a stent had fewer heart attacks, and those treated surgically had fewer strokes. Age also made a difference, they say — people younger than 70 did slightly better with while those over 70 had better results with surgery.

"We now have two safe and effective methods to treat disease that can be targeted to individual patients," says Mayo Clinic neurologist James Meschia, M.D., one of the study's principal co-authors. Such personalized decision-making should translate into improved patient outcomes.

Stroke, an interruption in blood flow to the brain, is the third leading cause of death in the United States. One major cause is the build-up of cholesterol in the carotid artery and the traditional effective treatment has been carotid endarterectomy (CEA), surgery to clear the blockage. More recently, vascular specialists have used carotid artery stenting (CAS), a less invasive procedure that involves threading a stent and expanding a small protective device in the artery to widen the blocked area and capture any dislodged plaque.

But it has been unclear what the comparative risks and benefits of these two procedures are. To find out, the National Institutes of Health funded the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST). One of the largest randomized stroke prevention trials ever undertaken, CREST enrolled 2,502 patients at 117 centers in the United States and Canada from 2000-2008.

Another strength of CREST is that it was conducted in large and small, public and private hospitals, Dr. Brott says. "The idea was to design a study that reflects the U.S. experience," he says.

Researchers specifically found that:

  • After a median follow-up of 2.5 years, there was no difference in the estimated four-year rates of the study's endpoints — early stroke, , or death and later stroke - between CAS versus CEA — 7.2 percent in the CAS group and 6.8 percent in the CEA group.
  • Differences were seen, however, depending on symptom status. In symptomatic patients, the rate of stroke and death in the estimated four-year rates was 8 percent in the CAS group and 6.4 percent in the CEA group, and in asymptomatic patients, the rates were 4.5 percent versus 2.7 percent respectively.
  • In the weeks following a procedure, there were differences in outcome between CAS and CEA (death .7 vs. .3 percent, stroke 4.1 vs. 2.3 percent, heart attack 1.1 vs. 2.3 percent).
  • There was a low risk of recurrent stroke in both CAS and CEA groups (2.0 vs. 2.4 percent).
Not only were outcomes good in symptomatic patients, they were even better in asymptomatic patients, which suggests the aggressive approach to stroke prevention in the U.S. is warranted, Dr. Brott says.

Limitations to the study include the fact that only one stent device was used and that CREST did not include an arm that randomized patients to use of drug therapy designed to prevent strokes.

"A vital next step is to understand the procedural risks of carotid stenting and in real world settings," says Walter J. Koroshetz, M.D., deputy director of the National Institute of Neurological Disorders and Stroke, which funded the trial.

Related Stories

Recommended for you

Ambitious global virome project could mark end of pandemic era

February 23, 2018
Rather than wait for viruses like Ebola, SARS and Zika to become outbreaks that force the world to react, a new global initiative seeks to proactively identify, prepare for and stop viral threats before they become pandemics.

Forecasting antibiotic resistance with a 'weather map' of local data

February 23, 2018
The resistance that infectious microbes have to antibiotics makes it difficult for physicians to confidently select the right drug to treat an infection. And that resistance is dynamic: It changes from year to year and varies ...

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.